Browsing category:

Anticonvulsant


While Brivaracetam is being evaluated as an adjunctive therapy in patients diagnosed with Epilepsy and partial onset seizures, animal models have piqued the curiosity of R&D experts as to Brivaracetam being a potential treatment for Alzheimer’s patients. As a unique product with a high-affinity synaptic vesicle protein 2A ligand, Brivaracetam is currently marketed by UCB,[…]

Read More

Known as the brand name anti-epileptic drug Dilantin, Phenytoin has recently piqued the interests of Multiple Sclerosis research and development teams. Study results shared from the National Hospital for Neurology and Neurosurgery in London have been hopeful for patients with MS who were treated with Phenytoin, in response to their cases of acute optic neuritis.[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service